

AMENDMENTS TO THE CLAIMS

This listing of Claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS

1)-40) CANCELED

41) (CURRENTLY AMENDED) A method for diagnosis of a stroke ~~neurological-ischemic~~ ~~deficit~~ in a patient comprising directly ~~or indirectly~~ measuring via latex agglutination, within three hours of stroke onset:

- a) the level of NR2A and/or NR2B NMDA receptor or fragment thereof in a subject; and
- b) the level of one or more agonists or antagonists of the NR2A and/or NR2B receptor; and
evaluating from the level of NR2A and/or NR2B NMDA receptor whether the stroke is ischemic or hemmorrhagic.

42) The method of claim 41 wherein the one or more agonists or antagonists comprise glutamate, polyglutamate, homocysteine and/or polyhomocysteine

43)-66) CANCELED

67) (NEW) The method of claim 41 further comprising administering ischemic or hemmorrhagic stroke therapy as appropriate.

68) (NEW) The method of claim 41 wherein the level of NR2A receptor or fragment thereof is measured substantially to the exclusion of the NR2B receptor or fragment thereof.

69) (NEW) The method of claim 41 wherein the level of NR2B receptor or fragment thereof is measured substantially to the exclusion of the NR2A receptor or fragment thereof.

70) (NEW) The method of claim 41 wherein the level of glutamate is measured.

71) (NEW) The method of claim 41 wherein the level of polyglutamate is measured.

72) (NEW) The method of claim 41 wherein the level of homocysteine is measured.

73) (NEW) The method of claim 41 wherein the level of polyhomocysteine is measured.